- Home
- HASI vs ZLAB Comparison
HASI vs ZLAB Comparison
Compare HASI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- ZLAB
- Stock Information
- Founded
- HASI 1981
- ZLAB 2013
- Country
- HASI United States
- ZLAB China
- Employees
- HASI N/A
- ZLAB N/A
- Industry
- HASI Real Estate Investment Trusts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HASI Real Estate
- ZLAB Health Care
- Exchange
- HASI Nasdaq
- ZLAB Nasdaq
- Market Cap
- HASI 3.3B
- ZLAB 3.4B
- IPO Year
- HASI 2013
- ZLAB 2017
- Fundamental
- Price
- HASI $28.02
- ZLAB $33.78
- Analyst Decision
- HASI Strong Buy
- ZLAB Strong Buy
- Analyst Count
- HASI 13
- ZLAB 3
- Target Price
- HASI $39.46
- ZLAB $55.00
- AVG Volume (30 Days)
- HASI 1.3M
- ZLAB 779.4K
- Earning Date
- HASI 02-13-2025
- ZLAB 02-27-2025
- Dividend Yield
- HASI 5.99%
- ZLAB N/A
- EPS Growth
- HASI 14.02
- ZLAB N/A
- EPS
- HASI 1.62
- ZLAB N/A
- Revenue
- HASI $140,172,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- HASI N/A
- ZLAB $49.04
- Revenue Next Year
- HASI $13.09
- ZLAB $46.80
- P/E Ratio
- HASI $17.33
- ZLAB N/A
- Revenue Growth
- HASI 2.29
- ZLAB 35.01
- 52 Week Low
- HASI $24.00
- ZLAB $13.48
- 52 Week High
- HASI $36.56
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- HASI 48.86
- ZLAB 79.95
- Support Level
- HASI $27.35
- ZLAB $30.61
- Resistance Level
- HASI $30.90
- ZLAB $33.00
- Average True Range (ATR)
- HASI 0.97
- ZLAB 1.32
- MACD
- HASI 0.08
- ZLAB 0.58
- Stochastic Oscillator
- HASI 26.90
- ZLAB 86.34
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is a climate investment firm that actively partners with clients to deploy real assets that facilitate the energy transition. It invests in behind-the-meter (BTM) building or facility-specific distributed energy projects which reduce energy usage or cost, Grid-connected (GC) renewable energy projects that deploy cleaner energy sources, such as solar, solar-plus-storage, and onshore wind, to generate power production and Fuels, Transport & Nature projects.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.